Erik Gatenholm

And it needs to look and feel just like human tissue so that the human cells can thrive within it.

So you basically create a synthetic environment in which you put your cells.

and and then you print a structure with that so instead of having that melted plastic you have really a syringe of of goo with human cells going around and printing a structure and is this i mean is this patented yes yes so we have a pattern on on bioink and we have a patent on some of the printing components you know most 3d printing is actually open source so you have to you have to be really innovative in this field not to kind of stand out yeah and so how are you guys going to make money who do you think you'll be selling to

So we're one of the first ones in the world to actually make this technology almost democratized.

So we're making it available for all scientists and researchers all over the world.

We want to have this bioprinter of ours, which is the incredible bioprinter.

We want to have it in every lab.

So we sell them for $5,000 to make it available for all the researchers.

We have sold about 40 so far.

We have about, we have about 82% margins on them.

Our gross margin is slightly more than that, actually.

Like 85-ish, 87?

Yeah, we're looking, yeah, 85.

You know, it depends on, we want to produce bulk, so we're kind of, if we can produce bulk, it gets a little higher, yeah.

exactly exactly everything in sweden everything in sweden everything is hand screwed by by the team that's impressive so so what do you guys think you'll do total 2016 revenue total 2016 revenue we're going to come up to approximately uh four four million dollars and the reason i say that so so the printer still is just small part of it but we actually our expertise allows us to print this human tissue for cosmetic companies and pharma companies all over the world to use these little tissue types

for testing of new cosmetic products or pharmaceutical drugs.

Got it.

So that's where the bulk revenues are in.

Absolutely.

Facebook, Eric Gatlin.